Corporate Board Profile
Tech Score: 13/100
2 mention(s) identify TYLER JACKS as having software/technology expertise.
| Company | Filing Date | Evidence | Reason |
|---|---|---|---|
| AMGEN INC | 2017-04-06 | Dr. Jacks is currently the David H. Koch Professor of Biology and director of the David H. Koch Institute for Integrative Cancer Research. | Dr. Jacks is a professor of biology and director of a cancer research institute, indicating a strong understanding of technology and research methodologies, which may include software applications. |
| THERMO FISHER SCIENTIFIC INC. | 2024-04-09 | Dr. Jacks currently serves as President of Break Through Cancer, an organization focusing on collaborative approaches to cancer research. | As a professor at MIT and founding director of a cancer research institute, he likely has a strong technical background, potentially including programming skills. |
| Filing Date | Source Excerpt |
|---|---|
| 2017-04-06 | Dr. Jacks is currently the David H. Koch Professor of Biology and director of the David H. Koch Institute for Integrative Cancer Research. |
| 2018-04-11 | Tyler Jacks joined the faculty of Massachusetts Institute of Technology, or MIT, in 1992 and is currently the David H. Koch Professor of Biology and director of the David H. Koch Institute for Integrative Cancer Research, which brings together biologists and engineers to improve detection, diagnosis and treatment of cancer, a position he has held since 2007. Dr. Jacks has been an investigator with the Howard Hughes Medical Institute, a nonprofit medical research organization, since 1994. Dr. Jacks has been a director of Thermo Fisher Scientific, Inc., a life sciences supply company, since 2009, serving on its Strategy and Finance Committee and scientific advisory board and chairing its Science and Technology Committee. In 2006, he co-founded T2 Biosystems, Inc., a biotechnology company, and served on its scientific advisory board until 2013. Dr. Jacks has served on the scientific advisory board of SQZ Biotech, a privately-held biotechnology company, since 2015. He was a consultant scientific advisor to Epizyme, Inc., a biopharmaceutical company, from 2007 to 2017. Dr. Jacks served on the scientific advisory board of Aveo Pharmaceuticals Inc., a biopharmaceutical company, from 2001 until 2013. In 2015, Dr. Jacks founded Dragonfly Therapeutics, Inc., a privately-held biopharmaceutical company, and serves as co-Chair of its scientific advisory board. He was appointed to the National Cancer Advisory Board, which advises and assists the Director of the National Cancer Institute with respect to the National Cancer Program, in 2011 and served as Chair until 2016. In 2016, Dr. Jacks was named to a blue ribbon panel of scientists and advisors established as a working group of the National Cancer Advisory Board and served as co-Chair advising the Cancer MoonshotSM Task Force. Dr. Jacks was a director of MIT's Center for Cancer Research from 2001 to 2007 and received numerous awards including the Paul Marks Prize for Cancer Research and the American Association for Cancer Research Award for Outstanding Achievement. He was elected to the National Academy of Sciences as well as the National Academy of Medicine in 2009 and received the MIT Killian Faculty Achievement Award in 2015. Dr. Jacks received an undergraduate degree from Harvard University and his doctorate from the University of California, San Francisco. The Board concluded that Dr. Jacks should serve on the Board based on his extensive scientific expertise relevant to our industry, including his broad experience as a cancer researcher, pioneering uses of technology to study cancer-associated genes, and service on several scientific advisory boards and membership in the National Cancer Advisory Board. |
| 2019-04-08 | Tyler Jacks joined the faculty of Massachusetts Institute of Technology... Committees: Audit, Compensation and Management Development... Director Compensation Table: Tyler Jacks total compensation 345,997. |
| 2020-04-07 | Tyler Jacks joined the faculty of Massachusetts Institute of Technology in 1992 and is currently the David H. Koch Professor of Biology... 2019 Director Compensation Table shows Tyler Jacks with total compensation of $339,114. |
| 2021-04-06 | Tyler Jacks is David H. Koch Professor of Biology at MIT. Director since 2012. Committees: Compensation and Management Development, Corporate Responsibility and Compliance. Director Compensation Table shows $324,899 total compensation. |
| 2022-04-05 | Tyler Jacks joined the faculty of Massachusetts Institute of Technology... Committees: Compensation and Management Development, Corporate Responsibility and Compliance... 2021 Director Compensation: Fees Earned or Paid in Cash $130,000, Stock Awards $209,970, All Other Compensation $0, Total $339,970. |
| 2023-04-06 | Tyler Jacks joined the faculty of Massachusetts Institute of Technology, or MIT, in 1992. ... Committees: Compensation and Management Development, Corporate Responsibility and Compliance ... 2022 Director Compensation: Tyler Jacks 359,774 USD. |
| 2024-04-17 | Tyler Jacks joined the faculty of Massachusetts Institute of Technology, or MIT, in 1992 and is currently the David H. Koch Professor of Biology, a position he has held since 2007, and founding director of the David H. Koch Institute for Integrative Cancer Research, which brings together biologists and engineers to improve detection, diagnosis and treatment of cancer, having served as director from 2007 to 2021. Since 2021, Dr. Jacks has served as President and director of Break Through Cancer, a foundation bringing together multidisciplinary cancer research teams selected from across five participating institutions. Dr. Jacks was an investigator with the Howard Hughes Medical Institute, a nonprofit medical research organization, from 1994 until 2021. Dr. Jacks has been a director of Thermo Fisher Scientific, Inc., a life sciences supply company, since 2009, serving as the Chair of its Science and Technology Committee and as a member of its Strategy and Finance Committee and its scientific advisory board. In 2006, he co-founded T2 Biosystems, Inc., a biotechnology company, and served on its scientific advisory board until 2013. Dr. Jacks served on the scientific advisory boards of SQZ Biotechnologies Company, a biotechnology company, from 2015 until 2023, and Aveo Pharmaceuticals Inc., a biopharmaceutical company, from 2001 until 2013. In 2015, he founded Dragonfly Therapeutics, Inc., a privately-held biopharmaceutical company, and serves as the Chair of its scientific advisory board. In 2011, he was appointed to the National Cancer Advisory Board, which advises and assists the Director of the National Cancer Institute with respect to the National Cancer Program, and served as Chair until 2016. Dr. Jacks was a director of MIT’s Center for Cancer Research from 2001 to 2007 and received numerous awards including the Paul Marks Prize for Cancer Research and the American Association for Cancer Research Award for Outstanding Achievement. He was elected to the National Academy of Sciences as well as the National Academy of Medicine in 2009 and received the MIT Killian Faculty Achievement Award in 2015. Dr. Jacks received an undergraduate degree from Harvard University and his doctorate from the University of California, San Francisco. |
| Filing Date | Source Excerpt |
|---|---|
| 2018-04-10 | The chairpersons of each of the Audit, Compensation, and Nominating and Corporate Governance Committees, as well as the chairpersons of the Strategy and Finance Committee of the Board, which Committee consists of Ms. Lewent (Chair), Messrs. Casper, Sørensen and Sperling, and Dr. Jacks, and the Science and Technology Committee of the Board, which Committee consists of Drs. Jacks (Chair) and Harris, and Mr. Casper, receive additional compensation for their services in those positions. |
| 2019-04-09 | Tyler Jacks David H. Koch Professor of Biology at the Massachusetts Institute of Technology and Director of the David H. Koch Institute for Integrative Cancer Research Science and Technology Strategy and Finance Summary Director Compensation Table Tyler Jacks Fees Earned or Paid in Cash: $140,000 Stock Awards: $175,165 All Other Compensation: $15,587 Total: $330,752 Proxy Statement 2019 |
| 2020-04-07 | Tyler Jacks Independent David H. Koch Professor of Biology at the Massachusetts Institute of Technology and Director of the David H. Koch Institute for Integrative Cancer Research Age: 59 Director since: 2009 Committees: Strategy and Finance, Science and Technology (Chair) Summary director compensation table Total: $350,615 |
| 2021-04-08 | Tyler Jacks Age: 60 Director since: 2009 Committees: Strategy and Finance, Science and Technology (Chair) ... Summary director compensation table ... Tyler Jacks Fees Earned or Paid in Cash $140,000 Stock Awards $195,138 All Other Compensation $15,535 Total $350,673 |
| 2022-04-07 | Tyler Jacks Age: 61 Director since: 2009 Committees: Strategy and Finance, Science and Technology (Chair) Director summary compensation table Tyler Jacks $143,132 Fees Earned or Paid in Cash, $200,144 Stock Awards, $490 All Other Compensation, Total $343,766. |
| 2023-04-07 | Tyler Jacks Age: 62 Director since: 2009 Committees: Strategy and Finance, Science and Technology (Chair) Dr. Jacks brings to the Board the benefits of his significant experience of many years in the cancer research industry. |
| 2024-04-09 | Dr. Jacks currently serves as President of Break Through Cancer, an organization focusing on collaborative approaches to cancer research. |
| 2025-04-08 | Tyler Jacks Age: 64 Director since: 2009 Committees: Strategy and Finance, Science and Technology (Chair) PROFESSIONAL HIGHLIGHTS • President, Break Through Cancer (2021 - Present) • Massachusetts Institute of Technology, Koch Institute • Professor, Department of Biology and Center for Cancer Research (1992 - Present) • Founding Director, Integrative Cancer Research (2001 - 2021) • Investigator, Howard Hughes Medical Institute (1994 - 2021) OTHER CURRENT DIRECTORSHIPS: • Amgen, Inc. DIRECTOR QUALIFICATIONS Dr. Jacks currently serves as President of Break Through Cancer, an organization focusing on collaborative approaches to cancer research, has worked for over 30 years as a professor in the Department of Biology at Massachusetts Institute of Technology, and previously served as Founding Director of the Koch Institute, a cancer research center. As a result of his many years of experience in the field of cancer research, including board-level and industry-specific service on public company boards, Dr. Jacks brings to the Board significant scientific, technological and industry expertise. Dr. Jacks also brings valuable board-level experience from his many years serving on public company boards and scientific advisory boards of biotechnology companies, pharmaceutical companies and academic institutions. Director compensation table shows total compensation of $345,836. |
Data sourced from SEC filings. Last updated: 2025-10-11